Ferring Pharmaceuticals Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.6M
Doctors Paid
37,533
Transactions
173,149
2024 Total
$2.0M
Payment Breakdown by Category
Consulting$5.0M (30.0%)
Food & Beverage$3.4M (20.4%)
Research$3.4M (20.2%)
Travel$1.2M (7.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5.0M | 1,061 | 30.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 1,909 | 21.0% |
| Food and Beverage | $3.4M | 162,916 | 20.4% |
| Unspecified | $3.4M | 133 | 20.2% |
| Travel and Lodging | $1.2M | 4,813 | 7.5% |
| Education | $77,481 | 2,290 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $30,835 | 14 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $18,000 | 6 | 0.1% |
| Grant | $5,400 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,500 | 5 | 0.0% |
Payments by Type
General
$13.2M
173,016 transactions
Research
$3.4M
133 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase II Study of Docetaxel Before Medical Castration with Degarelix in Patients with Newly Diagnosed Metastatic Prostatic Adenocarcinoma | $1.0M | 0 | 20 |
| Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer | $371,746 | 0 | 6 |
| Administration of FSH and Low Dose hCG for Oocyte Maturity While Decreasing hCG Exposure in IVF Cycles | $259,174 | 0 | 6 |
| A Prospective Pilot Study to Evaluate Efficacy and Safety of Euflexxa for the Treatment of Osteoarthritis | $235,856 | 0 | 6 |
| Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer | $216,424 | 0 | 3 |
| Combined Use of the Controlled Release Dinoprostone Insert and Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening and Labor Induction in Term Women A Randomized Controlled Trial | $116,717 | 0 | 5 |
| Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 CoQ10 Versus Those That Are Not a Pilot Study | $112,171 | 0 | 2 |
| A Trial of Cervadil dinoprostone PGE 2 insert for Outpatient Preinduction Cervical Ripening in Women at 39.0 to 41.6 weeks gestation | $103,427 | 0 | 3 |
| Clenpiq Low Residue Diet Study | $96,427 | 0 | 7 |
| A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer | $78,669 | 0 | 5 |
| Retrospective Study to Evaluate PatientsClinical Factors related to Positive Response from HA Injections | $78,030 | 0 | 2 |
| Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination with Degarelix in Men with Hormone-Sensitive Prostate Cancer | $66,688 | 0 | 21 |
| Randomized Comparison of the Impact of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid versus Polyethylene Glycol Bowel Preparation on Inpatient Colonoscopy Quality Parameters | $64,878 | 0 | 4 |
| The Impact of the Timing of Trigger on IVF Success | $52,773 | 0 | 2 |
| Pre-Implantation Screening and INvestigation on the Cryopreservation of Embryos PrISICE | $52,773 | 0 | 2 |
| Randomized Phase 1b2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer | $52,562 | 0 | 7 |
| Clinical Outcomes after Formal Cervidil Training COACT | $50,814 | 0 | 1 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet With the Use of the Clenpiq Bowel Purgative | $49,665 | 0 | 3 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet with the use of the Clenpiq Bowel Purgative | $40,000 | 1 | 1 |
| The Impact of the Timing of Trigger on IVF Success Randomized Control Trial | $33,057 | 0 | 3 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer MAGIC-8 | $29,895 | 0 | 1 |
| A Prospective, Randomized, Controlled Clinical Trial Evaluating the Superiority of Preimplantation Genetic Screening (PGS) and Deferred Transfer of Cryopreserved Embryos Over "Freeze-Only" Deferred Transfer Without PGS or Immediate Embryo Transfer During a "Fresh" In Vitro Fertilization Cycle | $26,387 | 0 | 3 |
| Evaluation of Follicular Fluid and Granulosa Cells from IVF Patients for Markers of Reproductive Aging | $25,465 | 0 | 3 |
| Nivolumab and BMS-986253 combined with Degarelix for Hormone-Sensitive Prostate Cancer | $19,538 | 0 | 3 |
| AMH and Doing Regimens for Initial IVF Stimulation Protocols | $18,818 | 0 | 1 |
| Degarelix Acetate Prior to Radiation Therapy | $16,259 | 0 | 1 |
| A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma. | $14,283 | 0 | 3 |
| Gonadotropin LHFSH-releasing hormone GnRH Antagonists Evaluation of Beneficial Effects for Alzheimers Disease | $11,234 | 0 | 1 |
| Association of fertility preservation health insurance benefit mandates with utilization of ART banking and philanthropic fertility drug programs among females newly diagnosed with cancer. | $10,080 | 0 | 1 |
| A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome | $9,382 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Grannum Sant, M.d, M.D | Urology | Bridgewater, NJ | $450,450 | $0 |
| Dr. Paul Feuerstadt, M.d, M.D | Gastroenterology | Hamden, CT | $382,135 | $0 |
| Dr. Fady Sharara, Md, MD | Reproductive Endocrinology | Reston, VA | $280,940 | $0 |
| Dr. Jason Griffith, Md, MD | Obstetrics & Gynecology | Spring, TX | $174,458 | $0 |
| Dr. John Park, M.d, M.D | Reproductive Endocrinology | Raleigh, NC | $155,670 | $0 |
| Dr. Michael Scheiber, M.d, M.D | Reproductive Endocrinology | Cincinnati, OH | $142,205 | $0 |
| Dr. Carl Crawford, M.d, M.D | General Acute Care Hospital | New York, NY | $133,950 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $120,485 | $0 |
| Dr. Angeline Beltsos, M.d, M.D | Reproductive Endocrinology | Chicago, IL | $110,542 | $0 |
| Robert Dimeff, Md, MD | Sports Medicine | Dallas, TX | $97,509 | $0 |
| Dr. Anurag Maheshwari, M.d, M.D | Hepatology | Baltimore, MD | $92,418 | $0 |
| Kevin Doody, Md, MD | Reproductive Endocrinology | Bedford, TX | $92,341 | $0 |
| Dino Delaportas, M.d, M.D | Infectious Disease | Bridgeport, WV | $87,224 | $0 |
| Sahil Khanna, Mbbs, MBBS | Internal Medicine | Rochester, MN | $87,119 | $0 |
| Roohi Najeemuddin, M.d, M.D | Reproductive Endocrinology | Chicago, IL | $85,273 | $0 |
| Unknown Provider | — | — | $83,232 | $0 |
| Mathew Nicholls, Md, MD | Orthopaedic Surgery | Bellevue, WA | $79,011 | $0 |
| Dr. Eric Ferkel, Md, MD | Orthopaedic Surgery | Van Nuys, CA | $78,030 | $0 |
| Elward Crawford, Md, MD | Urology | San Diego, CA | $77,767 | $0 |
| Dr. Timothy Miller, Md, MD | Gastroenterology | Temple, TX | $77,431 | $0 |
| Dr. Gerald Bertiger, Md, MD | Gastroenterology | Ephrata, PA | $73,049 | $0 |
| Dr. Monica Pasternak, M.d, M.D | Obstetrics & Gynecology | San Francisco, CA | $69,229 | $0 |
| Dr. Matt Rosenberg, M.d, M.D | Family Medicine | Jackson, MI | $67,790 | $0 |
| Dr. Ali Hassoun, Md, MD | Infectious Disease | Huntsville, AL | $67,354 | $0 |
| Dr. Amber Cooper, Md, MD | Reproductive Endocrinology | Saint Louis, MO | $66,232 | $0 |
Ad
Top Products
- MENOPUR $3.1M
- EUFLEXXA $2.0M
Associated Products (12)
- REBYOTA $3.9M
- FIRMAGON $3.1M
- EUFLEXXA $2.0M
- ADSTILADRIN $1.6M
- CLENPIQ $1.1M
- CERVIDIL $563,608
- ENDOMETRIN $476,911
- FIRMAGON 240 $394,398
- INVOCELL $257,492
- CIMZIA $243,508
- NOVAREL $56,006
- FIRMAGON 80 $11,234
Payment Categories
- Food & Beverage $3.4M
- Consulting $5.0M
- Travel & Lodging $1.2M
- Research $3.4M
About Ferring Pharmaceuticals Ltd.
Ferring Pharmaceuticals Ltd. has made $16.6M in payments to 37,533 healthcare providers, recorded across 173,149 transactions in the CMS Open Payments database. In 2024, the company paid $2.0M. The top product by payment volume is MENOPUR ($3.1M).
Payments were distributed across 192 medical specialties. The top specialty by payment amount is Reproductive Endocrinology ($2.7M to 930 doctors).
Payment categories include: Food & Beverage ($3.4M), Consulting ($5.0M), Research ($3.4M), Travel & Lodging ($1.2M).
Ferring Pharmaceuticals Ltd. is associated with 12 products in the CMS Open Payments database, including REBYOTA, FIRMAGON, and EUFLEXXA.